Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. (Research).

Results of experiments evaluating the efficacy of three immunization strategies for the prevention of West Nile virus (WNV) encephalitis are reported. Immunization strategies evaluated included a killed virus veterinary vaccine, a live attenuated chimeric virus vaccine candidate, and passive immunization with WNV-immune serum; all were tested by using a hamster model of the disease. Each product protected the animals from clinical illness and death when challenged with a hamster-virulent wild-type WNV strain 1 month after initial immunization. The live attenuated chimeric virus vaccine candidate induced the highest humoral antibody responses, as measured by hemagglutination inhibition, complement fixation, and plaque reduction neutralization tests. Although the duration of protective immunity was not determined in this study, our preliminary results and the cumulative experience of other virus vaccines suggest that the live attenuated chimeric virus provides the longest lasting immunity.

**********

After the appearance of West Nile virus (WNV) in North America and the resulting human and equine cases of encephalitis, considerable efforts have focused on developing vaccines against this emerging viral pathogen. A number of different WNV vaccine candidates have been recently described and are now in various stages of testing (1-4). A formalin-inactivated veterinary vaccine (West Nile Virus Vaccine, Killed, Fort Dodge Animal Health, Fort Dodge, IA) was conditionally licensed by the U.S. Department of Agriculture in August 2001 and has already been used in equines and exotic zoo birds in some areas of the country. We report the results of studies evaluating the efficacy of the killed veterinary vaccine, a live attenuated chimeric virus candidate, and passive immunization with immune serum for preventing WNV encephalitis in a hamster model of the disease (5,6).

Materials and Methods

Virus, Vaccines, and Immune Serum

The virus used to infect animals in these studies was a second Vero cell passage of strain NY385-99, originally isolated from the liver of a Snowy Owl (Nyctea scandiaca) that died at the Bronx Zoo during the 1999 WNV epizootic in New York City (7). Two different WNV vaccines were evaluated in the hamster model: West Nile Encephalitis Virus Vaccine (killed), (Fort Dodge Animal Health, Fort Dodge, IA), a formalin-inactivated whole virus veterinary vaccine, and ChimeriVax-West Nile virus (Acambis, Inc., Cambridge, MA), a live attenuated chimeric virus vaccine candidate

(1). The immune serum used in passive immunization experiments was prepared by pooling convalescent-phase serum samples of six hamsters that were bled 5 weeks after infection with WNV strain NY385-99.

Hamsters and Hamster Model

Animals used in these studies were adult (10-11 weeks old) female hamsters (Mesocricetus auratus) obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN). The hamster model of WNV encephalitis has been described (5,6). After intraperitoneal inoculation of [10.sup.4] tissue culture infectious [dose.sub.50] ([TCID.sub.50]) of WNV strain NY385-99, fatal encephalitis developed in approximately 50% of adult hamsters. Animals were cared for in accordance with the guidelines of the Committee on Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council) under an animal-care protocol approved by the University of Texas Medical Branch. All work with infected animals was carried out in biosafety level 3 facilities.

Immunization Schedule and Challenge with WNV

Hamsters immunized with West Nile Encephalitis Virus Vaccine (killed) received two intramuscular injections of 0.1 mL each, given 3 weeks apart, following manufacturer's recommendation. Eleven days after the second immunization, the hamsters were bled to determine their antibody response; each animal was then inoculated intraperitoneally with [10.sup.4] [TCID.sub.50] of WNV strain NY385-99. After challenge with live virus, the animals were bled daily for 6 consecutive days to measure the level of viremia and subsequent immune response. The animals were observed for another 21 days to determine if any developed signs of encephalitis or died.

Two groups of hamsters were inoculated intramuscularly with the ChimeriVax-WNV vaccine. One group received [10.sup.6.3] PFU, and the other received [10.sup.3.3] PFU of the chimeric virus. Thirty-one and 32 days, respectively, after injection of the virus, the two groups of hamsters were inoculated intraperitoneally with [10.sup.4] [TCID.sub.50] of WNV strain NY385-99. After challenge, the animals were bled daily for 6-7 days to measure the level of viremia and immune response, as described previously. These hamsters were also observed for 21 additional days for signs of illness or death.

Two groups of hamsters also were passively immunized with different amounts (0.1 mL and 0.5 mL) of hamster WNV-immune serum, given intramuscularly. One day after passive immunization, both groups of animals were bled to determine if detectable titers of WNV hemagglutination inhibition (HI) antibodies were present in their serum. The animals then were inoculated intraperitoneally with [10.sup.4] [TCID.sub.50] of WNV strain NY385-99, bled for 7 consecutive days, and observed for another 21 days, as described previously.

A group of naive (control) hamsters was also inoculated intraperitoneally with the same dosage of WNV strain NY385-99. Thirty-eight days after infection, 10 of the surviving animals were bled to determine their antibody response.

Virus Titration and Antibody Determinations

Serial blood samples from the hamsters were titrated in microplate cultures of the C6/36 clone of Aedes albopictus cells (8). The presence or absence of WNV viral antigen, determined by immunofluorescence, was used as the endpoint. This technique has been described in detail (5,6). WNV titers in the blood samples were calculated as the [TCID.sub.50] per microliter of specimen by the method of Reed and Muench (9).

Serum antibodies to WNV and Yellow fever virus (YFV) were measured by HI, complement fixation (CF), and plaque reduction neutralization (PRN) tests. Antigens for HI and CF tests were prepared from brains of newborn mice injected intracerebrally with the respective flaviviruses; these infected brains were treated by the sucrose-acetone extraction method (10). Hamster sera were tested by HI at serial twofold dilutions from 1:20 to 1:5,120 at pH 6.6 (WNV) or 6.4 (YFV) with 4 U of antigen and a 1:200 dilution of goose erythrocytes, following established protocols (10).

CF tests were performed by a microtechnique (10) with two full units of guinea pig complement and antigen titers [greater than or equal to] 1:32. Titers were recorded as the highest dilutions giving +3 or +4 fixation of complement on a scale of 0 to +4.

PRN tests on hamster serum were performed by a previously described technique (11) in 24-well, Vero-microplatecell cultures, using a fixed virus inoculum (~100 PFU) against varying serum dilutions (1:10 to 1:20,480). For PRN tests, the Egypt 101 strain of WNV (12) was used because this strain produced larger and sharper plaques than NY385-99. Hamster serum samples were diluted in phosphate-buffered saline, pH 7.4, containing 10% fresh guinea pig serum. Virus inoculum was mixed with an equal volume of each serum dilution; and the mixture was incubated overnight at 4[degrees]C. The following day, 50 uL of the serum-virus mixture was injected into Vero microplate cultures, with two wells per serum dilution. Virus plaques were read 4 days later; [greater than or equal to] 90% plaque reduction was used as the endpoint.

Results

WNV Infection in Naive Hamsters

The level and duration of viremia, antibody response, and deaths in naive (non-immune) adult hamsters after WNV infection have been described (5,6). Following intraperitoneal inoculation of [10.sup.4] [TCID.sub.50] of WNV strain NY385-99, moderate levels of viremia that persisted for 6 days developed in the hamsters (Figure). HI antibodies were detected in the animals as early as day 5, and titers continued to increase through day 7. Initially, HI antibody response in primary WNV infection is specific; but after 3 or 4 weeks, the antibody pattern becomes more broadly reactive and serologic cross-reactions occur with other flavivirus antigens (6). Table 1 shows the HI, CF, and PRN antibody responses to WNV antigen and virus in 10 naive adult hamsters that survived infection with the NY385-99 virus strain. These animals were bled 38 days after infection. Hamsters who survived infection with wild-type WNV appeared to have solid immunity 1 month after infection (Table 1). Convalescent-phase sera from some of these animals were used to prepare the WNV immune serum used in the passive immunization experiments described below.

WNV Infection in Hamsters Previously Immunized with a Killed Vaccine

Table 2 shows the HI, CF, and PRN antibody responses of nine hamsters 32 days after immunization (2 injections) with the Fort Dodge WNV killed vaccine. One month after the initial immunization, eight of nine animals had detectable levels of HI and CF antibodies; five of nine hamsters had low levels of WNV-neutralizing antibodies. Six days after challenge with the wild-type virus, most of the hamsters had an increase (range two-fold to 32-fold increase) in their HI and CF antibody titers, indicating some degree of antigenic stimulation and possible virus replication. Two of the hamsters had detectable levels of viremia after challenge with the wild-type virus (Table 3). However, none of the animals appeared clinically ill, and all survived.

WNV Infection in Hamsters Previously Immunized with Live, Attenuated Chimeric Vaccine

Tables 4 and 5 show the antibody responses of hamsters receiving two different doses ([10.sup.6.3] and [10.sup.3.3]) of ChimeriVax-WNV vaccine. The results of these two experiments were similar. One month after immunization, all animals had detectable HI, CF, and PRN-antibody titers to WNV. When tested 6-7 days after challenge with the wild-type virus, none of the animals had a substantial change in antibody titer. WNV was detected in the blood of one animal on day 2; the titer was [10.sup.0.7] [TCID.sub.50]/mL (data not shown). None of the animals in these two groups appeared sick, and all survived.

WNV Infection in Passively Immunized Hamsters

Two groups of hamsters (A and B) were inoculated with 0.5 mL and 0.1 mL, respectively, of hamster WNV-immune serum (Table 6). HI antibody titer of the immune serum was 1:1,280; PRN titer was 1:5,120. Twenty-four hours later, the animals were bled and then injected with the wild-type virus. When tested 24 hours after receiving WNV-immune serum, all animals in group A had low but detectable HI antibody titers. No HI antibodies in group B were detectable after 24 hours. Seven days after challenge with WNV, one animal in group A still had detectable HI antibodies. Hamsters in groups A and B were bled for 6 consecutive days; no virus was detectable in any of the blood samples (data not shown). All animals in groups A and B appeared well and survived challenge. The absence of an antibody response or viremia in the passively immunized animals suggests that no virus replication occurred after challenge with WNV.

Discussion

Each of the three immunization products evaluated in this study (killed whole virus vaccine, live attenuated chimeric virus vaccine, and passive immunization with immune serum) protected hamsters from clinical encephalitis and death upon subsequent challenge with the virulent wild-type WNV strain NY385-99. In contrast, fatal encephalitis developed in approximately 50% of naive hamsters inoculated with the same virus dose (5). One obvious deficiency of our study was that the duration of protection induced by each immunization product was not determined. Determining the duration of protection is difficult with a relatively short-lived (approximately 2 yrs) animal such as a hamster; such studies are more meaningful when conducted by using longer-lived species such as horses or humans. Nonetheless, the general experience with other live and inactivated vaccines and the use of immune globulin for prevention of viral diseases offers some clue as to the advantages and disadvantages of the three approaches for preventing WNV encephalitis (13,14).

Passive Immunization with WNV Immune Globulin

Hamsters inoculated with WNV immune serum (0.5 mL and 0.1 mL) appeared to be completely protected when challenged with the wild-type virus 24 hours after passive immunization (Table 6). No virus was detected in the animals' blood after challenge, and HI antibodies to WNV viral antigen did not develop. Immune globulins present in the WNV-immune serum probably inhibited virus replication; consequently, insufficient antigenic mass existed in the animals to stimulate an antibody response. One advantage of passive immunization with WNV-immune globulins is that the protective effect is almost immediate (<24 hours in the case of the hamsters in our experiment). Passive immunization with WNV-immune globulins might be desirable when rapid, temporary protection against the virus is needed or when a person with a compromised immune system requires protection. The major disadvantage of passive immunity acquired from immune globulins is the relatively short period of protection (13).

Inactivated WNV Vaccine

Most hamsters immunized with the Fort Dodge killed WNV vaccine had low levels of HI, CF, and PRN antibodies after two injections (Table 2). None of the animals that received the killed vaccine appeared clinically ill or died after challenge with the wild-type WNV. However, six of the nine hamsters had a substantial increase in their HI antibody titer after challenge with the wild-type virus; two of the nine animals subsequently had detectable viremia (Table 3). These data suggest that the immune response to the killed vaccine was insufficient to completely inhibit virus replication and that some degree of virus replication occurred after challenge with the wild-type virus.

The Fort Dodge WNV veterinary vaccine used in this study is a commercially available formalin-inactivated whole virion preparation that has received conditional approval from the U.S. Department of Agriculture for use in horses. The first WNV vaccine approved for use in the United States, its substrate and degree of purification are not public information. Duration of protection with this vaccine is also unknown, although the manufacturer recommends that horses be immunized annually.

The major advantage of killed vaccines is their safety; the disadvantages are that they often require multiple doses to elicit and sustain an effective immune response and that the immune response may be imbalanced, leading to subsequent potentiation of the disease (14,15). However, highly purified killed-virus vaccines have been used effectively in persons for the prevention of Japanese encephalitis virus and Tick-borne encephalitis virus (16,17).

Live, Attenuated Chimeric WNV

Hamsters receiving both doses ([10.sup.6.3] or [10.sup.3.3] PFU) of the ChimeriVax-WNV had good HI and PRN-antibody responses to WNV, when tested 1 month after immunization (Tables 4 and 5). One animal (H-8183) did not develop CF antibodies after immunization, and two other hamsters were not tested. Notably, CF antibodies to WNV viral antigen developed in most of the hamsters after vaccination with the ChimeriVax-WNV, although humans without previous flavivirus exposure generally do not develop CF antibodies after administration of the 17D vaccine (18). The ChimeriVax technology platform uses YFV 17D as a live vector for envelope genes of WNV (1).

Six and 7 days after challenge with the wild-type virus, we found no change in HI or CF titers of the animals previously immunized with the ChimeriVax-WNV (Tables 4 and 5). PRN titers were not tested after challenge. WNV was detected in the blood of a single animal on day 2, although WNV antibody titers did not increase in the blood of this hamster 6 days after challenge. These data suggest that minimal WNV replication occurred in the animals immunized with the chimeric virus when challenged with the wild-type virus. The levels of PRN antibodies present in ChimeriVax-WNV--immunized hamsters also suggest that the protection would be long lasting.

The major advantages of live attenuated virus vaccines are that they induce a more balanced immune response and that the resulting immunity is longer lasting than with killed vaccines or immune globulins (13-15). Major concerns with a live WNV vaccine are related to safety: 1) a potential vaccine might contain adventitious agents; 2) the vaccine virus might cause illness in some recipients or lose attenuation during manufacture or replication; and 3) stability. The second and third concerns are currently being investigated and addressed; results will be reported in subsequent publications. However, on balance, the ChimeriVax-WNV candidate vaccine appears to be quite effective in preventing WNV encephalitis, on the basis of our comparative studies in a hamster model of the disease.

Table 1. Hemagglutination inhibition, complement fixation, and plaque
reduction neutralization antibody responses of naive adult golden
hamsters that survived West Nile virus infection (a, b)

              HI antibody    CF antibody
               titer WNV      titer WNV            WNV PRN anti-
Animal no.      antigen      antigen (c)           body titer (d)

H-8589          1:1280          1:320                 1:10,240
H-8590           1:640          1:160                 1:10,240
H-8591           1:640          1:320                  1:5120
H-8592           1:640           1:80                  1:2560
H-8593           1:640          1:160                  1:2560
H-8594          1:1280          1:160                  1:5120
H-8595          1:1280          1:320                 1:10,240
H-8596          1:1280          1:320          [greater than or equal
                                                    to] 1:20,480
H-8597          1:1280          1:320                  1:5120
H-8598          1:1280          1:640                  1:2560

(a) HI, hemagglutination inhibition; CF, complement fixation; PRN,
plaque reduction neutralization; WNV, West Nile virus.

(b) Animals 38 days after inoculation of virus strain NY385-99
([10.sup.4.0] tissue culture infective [dose.sub.50] given
intraperitoneally).

(c) WNV antigen titer = [greater than or equal to] 1:32.

(d) Highest serum dilution producing >90% plaque inhibition.

Table 2. WNV antibody response of hamsters after immunization with
WNV killed virus vaccine (Fort Dodge) and challenge with the NY38599
strain of WNVa (a, b)

            HI antibody    CF antibody    PRN antibody
Animal no.     titer          titer        titer (c)

32 days after Ft. Dodge vaccine
  H-8440       1:40           1:40            1:20
  H-8441       0 (d)            0            <1:10
  H-8442       1:20           1:40           <1:10
  H-8443       1:40           1:40            1:20
  H-8445       1:40           1:40            1:20
  H-8446       1:20           1:20            1:40
  H-8447       1:20           1:20           <1:10
  H-8448       1:20           1:20           <1:10
  H-8449       1:40           1:20            1:10
6 days after challenge with WNV
  H-8440       1:80           1:80             ND
  H-8441       1:320          1:160            ND
  H-8442       1:40           1:40             ND
  H-8443       1:40           1:40             ND
  H-8445       1:320          1:160            ND
  H-8446       1:80           1:40             ND
  H-8447       1:320          1:160            ND
  H-8448       1:160          1:80             ND
  H-8449       1:160          1:40             ND

(a) WNV, West Nile virus; HI, hemagglutination inhibition; CF,
complement fixation; PRN, plaque reduction neutralization; ND, not
done.

(b) [10.sup.4.0] 50% tissue culture infective [dose.sub.50] given
intraperitoneally.

(c) Highest serum dilution producing >90% plaque inhibition.

(d) 0 = <1:20.

Table 3. Level and duration of viremia in hamsters previously immunized
with WNV killed virus vaccine (Fort Dodge) and challenged with
the NY385-99 strain of WNV (a)

                      Postinfection, by day

Animal no.      1       2      3      4      5     6

8440          0 (b)    0      0      0      0      0
8441          0        1.2    3.5    1.3    1.2    0
8442          0        0      0      0      0      0
8443          0        0      0      0      0      0
9445          0        0      0      0      0      0
8446          0        0      0      0      0      0
8447          0        0      0      0      0      0
8448          0        0.7    3.0    4.3    2.3    0
8449          0        0      0      0      0      0

(a) WNV, West Nile virus.

(b) Virus titers in blood expressed as [log.sub.10] 50% tissue culture
infective [dose.sub.50]/mL of blood. 0 = [<10.sup.0.7] TCI[D.sub.50].

Table 4. Antibody response of adult golden hamsters to intramuscular
inoculation of 1.8 X [10.sup.6] of ChimeriVax-WNV and subsequent
challenge with WNV ([10.sup.4.0] TCI[D.sub.50] given
intraperitoneally) (a)

                  HI antibody titer             CF antibody titer

Animal no.    YFV antigen    WNV antigen    YFV antigen    WNV antigen

31 days after ChimeriVax-WNV
H-8183           1:40           1:160          0 (c)             0
H-8184           1:40           1:160          0                ND
H-8185           1:40           1:160          0               1:20
H-8186           1:80           1:320          0               1:40
H-8187           1:40           1:160          0               1:20
H-8188           1:40           1:160          0               1:20
H-8189           1:80           1:320          0               1:40
H-8190           1:40           1:160          0               1:20
H-8191           1:80           1:160          0               1:20
H-8192           1:40           1:160          0               1:40
6 days after challenge with WNV
H-8183           1:20           1:160          0                 0
H-8184           1:40           1:160          0               1:40
H-8185           1:20           1:160          0               1:20
H-8186           1:80           1:320          0               1:40
H-8187           1:20           1:160          0               1:20
H-8188           1:40           1:160          0               1:20
H-8189           1:80           1:320          0               1:40
H-8190           1:40           1:320          0               1:40
H-8191           1:40           1:320          0               1:20
H-8192           1:40           1:160          0               1:20

                     antibody titer (b)

Animal no.                WNV PRN

31 days after ChimeriVax-WNV
H-8183                     1:160
H-8184                     1:160
H-8185                     1:640
H-8186                     1:320
H-8187        [greater than or equal to] 1:640
H-8188                     1:640
H-8189                     1:640
H-8190                     1:320
H-8191                      1:80
H-8192                      1:80
6 days after challenge with WNV
H-8183                       ND
H-8184                       ND
H-8185                       ND
H-8186                       ND
H-8187                       ND
H-8188                       ND
H-8189                       ND
H-8190                       ND
H-8191                       ND
H-8192                       ND

(a) WNV, West Nile virus; HI, hemagglutination inhibition; CF,
complement fixation; PRN, plaque reduction neutralization; YFV, Yellow
fever virus; ND, not done.

(b) Highest serum dilution producing [greater than or equal to] 90%
plaque inhibition.

(c) 0 = <1:20.

Table 5. Antibody response of adult golden hamsters to intramuscular
inoculation of 1.8 X [10.sup.3] of ChimeriVax-WNV and WNV[10.sup.4.0]
TCI[D.sub.50] given intraperitoneally (a)

                  HI antibody titer             CF antibody titer

Animal no.    YFV antigen    WNV antigen    YFV antigen    WNV antigen

32 days after ChimeriVax-WNV
H-8322           1:40           1:160         0 (c)           1:20
H-8323           1:20           1:80             0            1:40
H-8324           1:80           1:320          1:20           1:80
H-8325           1:40           1:320            0            1:80
H-8326           1:40           1:320            0            1:80
H-8327           1:40           1:320           ND             ND
H-8328           1:80           1:320          1:20           1:80
H-8329           1:40           1:320            0            1:80
7 days after challenge with WNV
H-8322           1:40           1:320            0            1:20
H-8323           1:40           1:160            0            1:20
H-8324           1:80           1:320            0            1:40
H-8325           1:80           1:320            0            1:80
H-8326           1:80           1:320            0            1:40
H-8327           1:40           1:160            0            1:20
H-8328           1:80           1:320            0            1:40
H-8329           1:40           1:320            0            1:80

                     antibody titer (b)

Animal no.                WNV PRN

32 days after ChimeriVax-WNV
H-8322                     1:320
H-8323                     1:160
H-8324                     1:160
H-8325        [greater than or equal to] 1:640
H-8326                     1:320
H-8327                     1:320
H-8328                      1:80
H-8329                      1:80
7 days after challenge with WNV
H-8322                       ND
H-8323                       ND
H-8324                       ND
H-8325                       ND
H-8326                       ND
H-8327                       ND
H-8328                       ND
H-8329                       ND

(a) WNV, West Nile virus; HI, hemagglutination inhibition; CF,
complement fixation; PRN, plaque reduction neutralization; YFV, Yellow
fever virus; ND, not done.

(b) Highest serum dilution producing [greater than or equal to] 90%
plaque inhibition.

(c) 0 = <1:20.

Table 6. WNV hemagglutination inhibition antibody titers in adult
hamsters 24 h after inoculation (passive immunization) with WNV immune
serum, and 7 days later after challenge with WNV ([10.sup.4.0]
TCI[D.sub.50] given intraperitoneally) (a)

Hamster no.    24 h after passive    7 days after challenge
                  immunization              with WNV

Group A--received 0.5 mL WNV immune serum
H-8126              1:40 (b)                  0
H-8127              1:20                      0
H-8128              1:20                      0
H-8129              1:20                      0
H-8130              1:20                      0
H-8138              1:40                      0
H-8139              1:40                      1:10
Group B--received 0.1 mL WNV immune serum)
H-8131              0                         0
H-8132              0                         0
H-8133              0                         0
H-8134              0                         0
H-8135              0                         0
H-8136              0                         0
H-8137              0                         0

(a) WNV, West Nile virus.

(b) Hemagglutination inhibition antibody titer. 0 = <1:10.

Acknowledgments

The authors thank Dora Salinas for help in preparing the manuscript.

This work was supported by grants Al-10984 and AI-50175 from the National Institutes of Health and by contract U50/CCU620541 from the Centers of Disease Control and Prevention.

References

(1.) Monath TP. Prospects for the development of a vaccine against the West Nile virus. Ann NY Acad Sci 2001;951:1-12.

(2.) Davis BS, Chang G-JJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001;75:4040-7.

(3.) Lustig S, Olshevsky U, Ben-Nathan D, Lachmi BE, Malkinson M, Kobiler D, et al. A live, attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immunol 2000; 13:401-10.

(4.) Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A 2002;99:3036-41.

(5.) Xiao S-Y, Guzman H, Zhang H, Travassos da APA, Tesh, RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 2001;7:714-21.

(6.) Tesh RB, Travassos da Rosa APA, Guzman H, Araujo TP, Xiao-SY. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 2002;8:245-51.

(7.) Steele KE, Linn M J, Schoepp RI, Komar N, Geisbert TW, Manduca RM, et al. Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol 2000;37:208-24.

(8.) Tesh RB. A method for the isolation of dengue viruses, using mosquito cell cultures. Am J Trop Med Hyg 1979;28:1053-9.

(9.) Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1938;27:493-7.

(10.) Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic procedures for viral, rickettsial and chlamydial infections. 7th ed. Washington: American Public Health Association; 1995. p. 189-212.

(11.) Bartelloni P J, Tesh RB. Clinical and serologic responses of volunteers infected with phlebotomus fever virus (Sicilian type). Am J Trop Med Hyg 1976;25:456-62.

(12.) Melnick JL, Paul JR, Riordan JT, Barnett VH, Goldblum N, Zabin E. Isolation from human serum in Egypt of a virus apparently identical to West Nile virus. Proc Soc Exp Biol Med 1951;77:661-5.

(13.) Stiehm ER. Passive immunization. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th ed. Vol. 2. Philadelphia: WB Saunders Company; 1998. p. 2769-802.

(14.) Murphy BR, Chanock RM. Immunization against viral diseases. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, et al., editors. Fields virology. 4th ed., Vol. 1. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 435-67.

(15.) Watson JC, Peter G. General immunization practices, In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders Company; 1999. p. 47-73.

(16.) Tsai TF, Chang G-JJ, Yu YX. Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders Company; 1999. p. 672-710.

(17.) Barrett PN, Dorner F, Plotkin SA. Tick-borne encephalitis vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders Company; 1999. p. 767-80.

(18.) Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders Company; 1999. p. 815-80.

Robert B. Tesh, * Juan Arroyo, ([dagger]) Amelia P.A. Travassos da Rosa, * Hilda Guzman, * Shu-Yuan Xiao, * and Thomas P. Monath ([dagger])

* University of Texas Medical Branch, Galveston, Texas, USA; and ([dagger]) Acambis, Inc., Cambridge, Massachusetts, USA

Juan Arroyo and Thomas P. Monath are employees of Acambis, Inc., which developed the ChimeriVax-West Nile vaccine candidate.

Address for correspondence: Robert B. Tesh, Department of Pathology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0609, USA; fax: [phone]; e-mail: [e-mail]